Nearly 85% of the 1.7 million adolescents with HIV live in sub-Saharan Africa, along with half of the nearly 40 million ...
Tecovirimat failed to reduce clade II mpox lesions, pain or viral clearance among participants in a study of the antiviral ...
The following is a summary of “St Andrews Referral Delay in Skin Cancer (StARDISC): A study of keratinocyte skin cancer time ...
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...
The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox,” said Past ACTG Chair Judith Currier M.D., M.Sc. “There was considerable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results